Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modern Molecular Taxonomy

Modern Molecular Taxonomy

Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of an Enhanced Recovery after Surgery Protocol in Postoperative Pain and Opioid Consumption after Rhinoplasty.

Facial plastic surgery & aesthetic medicine·2026

Same author

Retraction notice to " Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell Carcinoma"[Clinical Genitourinary Cancer 23/6 (2025) 102422].

Clinical genitourinary cancer·2026

Same author

Real-World Experience With Prostate-Specific Membrane Antigen-Positron Emission Tomography in Primary Staging and Biochemical Recurrence Settings: Data From the Michigan Urological Surgery Improvement Collaborative.

Urology practice·2026

Same author

The Effect of Patient Resources on Outcomes in Autologous Breast Reconstruction: A Single Center Matched Cohort Study.

Journal of reconstructive microsurgery·2026

Same author

People Living with HIV Eligibility in Canadian Cancer Clinical Trials.

Current oncology (Toronto, Ont.)·2026

Same author

Accountable Care Organization Efficiency on Entry and Shared Savings Bonuses.

JAMA network open·2026

Same journal

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

JNCI cancer spectrum·2026

Same journal

Response to bates.

JNCI cancer spectrum·2026

Same journal

RE: Rural-urban disparities and trends in cancer screening: an analysis of Behavioral Risk Factor Surveillance System data (2018-2022).

JNCI cancer spectrum·2026

Same journal

Pandemic-era increases in late-stage pediatric cancer diagnoses, 2020-2022.

JNCI cancer spectrum·2026

Same journal

Engaging Community Oncology Stakeholders to Plan Multi-site Cancer Caregiving Research (CONNECT WF-2300CD).

JNCI cancer spectrum·2026

Same journal

Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis.

JNCI cancer spectrum·2026

See all related articles

Search research articles

Home
Understanding Randomized Controlled Trial Generalizability Through An Embedded Molecular Diagnostics Trial.

Home
Understanding Randomized Controlled Trial Generalizability Through An Embedded Molecular Diagnostics Trial.

Related Experiment Video

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial.

Patrick Lewicki¹, Arnav Srivastava¹, Ralph Jiang²

¹Department of Urology, University of Michigan, Ann Arbor, MI, United States.

JNCI Cancer Spectrum

|April 24, 2026

View abstract on PubMed

Summary

This summary is machine-generated.

Randomized controlled trials (RCTs) may have generalizability issues due to differing patient management, not just participant selection. Real-world data shows shorter treatment times compared to RCTs, suggesting management variations impact outcomes.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Related Experiment Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Area of Science:

Urology
Oncology
Clinical Trials

Background:

Randomized controlled trials (RCTs) are crucial for establishing treatment efficacy, but their generalizability to real-world settings is often questioned.
Differences in patient management between clinical trial contexts and routine practice may contribute to observed outcome disparities.
The impact of a genomic classifier (GC) on treatment decisions for high-risk prostate cancer post-radical prostatectomy (RP) was evaluated in the G-MINOR RCT.

Purpose of the Study:

To investigate whether differences in patient management contribute to generalizability issues in randomized controlled trials (RCTs).
To compare the management and treatment patterns of high-risk prostate cancer patients undergoing radical prostatectomy (RP) within an RCT versus a real-world setting.

Main Methods:

The study compared patients within the G-MINOR RCT (N=338) to propensity score-matched cohorts from the Michigan Urological Surgery Improvement Collaborative (MUSIC) (N=1014 contemporary, N=338 pre-trial).
Rates and time to secondary treatment (adjuvant or salvage therapy) after RP were analyzed.
Key clinicopathologic factors were controlled for in the analysis.

Main Results:

Patients in the real-world MUSIC cohorts received secondary treatment more frequently and sooner after RP compared to G-MINOR RCT participants.
Estimated 2-year treatment-free survival was significantly lower in the real-world cohort (74%) compared to the RCT cohort (84%).
Significant differences in management were observed even after stratifying patients by genomic risk.

Conclusions:

Patient management strategies differ significantly between RCTs and real-world settings, even when controlling for clinical and genomic factors.
These management variations, beyond participant selection, pose challenges to the generalizability of RCT findings.
Discrepancies in patient outcomes observed between RCTs and real-world data may be partly explained by these differing management approaches.